Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H22FN3O5 |
| Molecular Weight | 415.4149 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@]1(CC(=NO1)C2=C3C=CC=CC3=CC=N2)C(=O)N[C@H]4CC(=O)O[C@]4(O)CF
InChI
InChIKey=VYFGDLGHHBUDTQ-ZLGUVYLKSA-N
InChI=1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1
| Molecular Formula | C21H22FN3O5 |
| Molecular Weight | 415.4149 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nivocasan (aka GS-9450) was discovered by LG Life Sciences and developed by Gilead Sciences. Nivocasan is an irreversible inhibitor of caspase 1, 8, and 9, and therefore able to prevent apoptosis. Nivocasan has been investigated as a treatment option for Hepatic fibrosis and Non-alcoholic steatohepatitis related to Hepatitis C infection. It had advanced to Phase II clinical trials before the development program was suspended.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P29466 Gene ID: 834.0 Gene Symbol: CASP1 Target Organism: Homo sapiens (Human) Sources: http://europepmc.org/abstract/MED/21667042 |
|||
Target ID: Q14790|||Q15780|||Q96T22 Gene ID: 841.0 Gene Symbol: CASP8 Target Organism: Homo sapiens (Human) Sources: http://europepmc.org/abstract/MED/21667042 |
|||
Target ID: P55211|||Q9UEQ3 Gene ID: 842.0 Gene Symbol: CASP9 Target Organism: Homo sapiens (Human) Sources: http://europepmc.org/abstract/MED/21667042 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22006541
Patients with Human Chronic Hepatitis C virus (HCV) and suffering from nonalcoholic steatohepatitis (NASH) were administered up to 40 mg of Nivocasan orally once daily for 4 weeks followed by a four week period with no dosing.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:56:51 GMT 2025
by
admin
on
Mon Mar 31 19:56:51 GMT 2025
|
| Record UNII |
9554OW6MVU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2105721
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
9352
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
WW-93
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
11633038
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
300000034309
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
908253-63-4
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
DB12720
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
C98213
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY | |||
|
9554OW6MVU
Created by
admin on Mon Mar 31 19:56:51 GMT 2025 , Edited by admin on Mon Mar 31 19:56:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|